Testosterone Dose Titration
Dialing In the Dose: Trough Targets and the Endocrine Society Range
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Testosterone FDA Approved for diagnosed hypogonadism; titration follows clinical guidelines
- WADA
- Prohibited (S1 Anabolic Agent)
Reference only. Not medical advice.
What can go wrong
Titrating to symptoms alone, without lab anchoring, risks dose creep into supraphysiological territory with rising hematocrit and estradiol. Conversely, fixating on a high target number rather than symptom relief drives unnecessary dose escalation. The Endocrine Society emphasizes mid-normal targeting and symptom-based assessment.
This is something to take to a clinician. The Atlas can tell you what is known about testosterone dose titration in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Dose titration is the iterative process of adjusting testosterone dose and timing to land serum levels within the adult male reference range while resolving symptoms. The Endocrine Society guideline frames the target as the mid-normal range (the reference range is roughly 300-1000 ng/dL), with parenteral protocols often checked at the trough (immediately before the next injection) and sometimes at peak (24-48 hours after). Good titration chases symptom relief at the lowest effective dose, not the highest tolerable level.
The goal is the middle of the range, not the top of it.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Because esterified testosterone produces a peak-trough cycle, where in that cycle a level is drawn determines the number. Clinicians titrate against a defined point, usually the trough for injectables, so that the lowest point of the cycle still sits comfortably in range, which keeps the peak from running supraphysiological.
- Titration anchor
- Trough (parenteral) or steady-state (transdermal)
- Adjustment cadence
- Re-check ~6-12 weeks after a change
- Target
- Mid-normal, lowest effective dose
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks. Dose changes should be lab-confirmed and symptom-guided.
Replacement is not the same as a cycle
Titration is the discipline that keeps replacement physiological. The same process, aimed at peaks well above 1000 ng/dL, becomes anabolic dosing, distinguishable from replacement chiefly by the target level and the resulting hematologic, lipid, and cardiovascular risk profile.
What it does to fertility
Any dose sufficient to relieve hypogonadal symptoms via exogenous testosterone suppresses the HPG axis and spermatogenesis; there is no replacement dose that is reliably fertility-sparing. Men wishing to preserve fertility should consider SERM or hCG-based strategies.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total testosterone at a standardized time point
- Estradiol
- Hematocrit/CBC
- PSA (age-appropriate)
- Symptom assessment
What people get wrong
Often saidHigher numbers always mean better results
ActuallyBeyond symptom resolution within the normal range, higher levels add side-effect risk, not proportional benefit; the Endocrine Society targets mid-normal.
Often saidOne blood draw tells you your level
ActuallyFor injectables, the number depends entirely on where in the peak-trough cycle it was drawn; timing must be standardized.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
Injectable titration uses trough (and sometimes peak) levels; transdermal and gel titration uses a steady-state level a few hours after application; pellet titration is constrained because the dose cannot be reduced once implanted. Oral testosterone undecanoate has its own meal-dependent kinetics requiring product-specific timing.
At a glance
- Reference range
- ~300-1000 ng/dL (10.4-34.7 nmol/L)
- Trough draw
- Immediately before next injection
- Peak draw (parenteral)
- 24-48 hrs post-injection
- Goal
- Mid-normal range with symptom resolution
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Testosterone Dose Titration. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Endocrine Society Clinical Practice Guideline: Testosterone Therapy in Men With Hypogonadism2018
Recommends targeting mid-normal range and measuring trough/peak appropriately for parenteral therapy